Can a cancer drug help heal chronic brain bleeds without surgery?

NCT ID NCT07729098

Not yet recruiting Disease control Sponsor: Dheeraj Gandhi Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding a single dose of the drug bevacizumab directly into the brain's lining artery can improve the standard minimally invasive procedure for chronic subdural hematoma — a slow brain bleed common in older adults. Up to 18 adults who are already scheduled for middle meningeal artery embolization will receive the drug during the same procedure. The main goal is to check safety and find the best dose, while also tracking whether the bleed shrinks more than with embolization alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) given directly into the artery of the brain lining
What this could lead to: If safe and effective, this combination approach could offer a less invasive way to treat chronic subdural hematoma and reduce the need for surgical drainage.
What could go wrong: This is a very early phase 1 trial with only 18 participants, so safety and dosing are still being explored. Bevacizumab carries risks of bleeding and impaired wound healing, especially when given into a brain artery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SUBDURAL HEMATOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SUBDURAL HEMATOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.